2-Apr-2026
TipRanks (Thu, 2-Apr 3:00 PM ET)
TipRanks (Wed, 1-Apr 3:25 PM ET)
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
TipRanks (Tue, 31-Mar 1:23 PM ET)
NervGen Pharma FY GAAP EPS of -$0.61
Seeking Alpha News (Tue, 31-Mar 9:21 AM ET)
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
Globe Newswire (Tue, 31-Mar 7:45 AM ET)
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
Globe Newswire (Thu, 12-Mar 4:15 PM ET)
Globe Newswire (Wed, 4-Mar 7:30 AM ET)
NervGen Pharma to Participate at Upcoming Investor Conferences
Globe Newswire (Wed, 18-Feb 7:30 AM ET)
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
Globe Newswire (Thu, 12-Feb 4:15 PM ET)
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
Globe Newswire (Wed, 11-Feb 7:00 AM ET)
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
Nervgen Pharma Corp. trades on the NASDAQ stock market under the symbol NGEN.
As of April 2, 2026, NGEN stock price declined to $4.26 with 606,832 million shares trading.
NGEN has a beta of 1.71, meaning it tends to be more sensitive to market movements. NGEN has a correlation of 0.06 to the broad based SPY ETF.
NGEN has a market cap of $337.45 million. This is considered a Small Cap stock.
NGEN support price is $4.18 and resistance is $4.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NGEN shares will trade within this expected range on the day.
